OUR TEAM Tom Bond MBA, CPA Director, The Yield

New Post Public Reply Private Reply Replies (0) Message Board
nlightn
419
OUR TEAM


Tom Bond
MBA, CPA
Director, The Yield Growth Corp.
Chairman of the Board, Urban Juve Provisions Inc.

tombond-placeholder-team-uai-552x736.jpg

Thomas Bond has over 35 years experience partnering with entrepreneur businesses to build and deliver the operational and financial infrastructure to support annual double-digit revenue growth. During that time, he has held C-level financial and operational positions with companies engaged in cosmetics, apparel, and construction including M.A.C Cosmetics, Cover FX Skin Care and Tridel.

Thomas was with M.A.C Cosmetics from 1993 until its sale to Estee Lauder in 1999. He started as the CFO and in 1994 the COO role was added to his portfolio. From 1993 to 1999, annual revenues at M.A.C Cosmetics grew from $12 million to over $300 million. His achievements included building an executive team that could support the growth objectives, opening M.A.C owned retail stores, diversifying the business geographically by expanding into the U.K., France, Italy and Hong Kong, and mitigating the retailer concentration risk in the U.S. by adding distribution agreements with a number of major department stores. He was personally responsible for leading the discussions with Estee Lauder and negotiating the final sale agreement. After the acquisition, he continued to provide full time consultant services to M.A.C Cosmetics until 2002. Thomas holds an MBA from the Rotman School of Business at the University of Toronto and is a CPA. C.A.

Penny Green
LLB, BA
Director, President & CEO, The Yield Growth Corp.
CEO, Urban Juve Provisions Inc.

2017-Glance-Pay-0712-1-uai-678x905.jpg

Penny is Co-Founder, President and CEO of The Yield Growth Corp. Penny has been recognized on PROFIT Magazine’s W100 list of top Canadian female entrepreneurs. Under her leadership as CEO, her law firm Bacchus Law was in the PROFIT 500 Fastest Growing companies in 2015 and 2016. Penny has deep experience in capital markets and has been involved in over 100 going public transactions. Penny was also a Co-Founder and initial director and officer of Merus Labs Inc. (TSX:MSL, NASDAQ:MSLI-Q) which was acquired by Norgine B.V. in July 2017 for $342 million.

Penny regularly participates as a speaker for keynotes and panels on Fintech, Capital-raising and Blockchain including CryptoHQ alongside the World Economic Forum in Davos. Penny has been featured in The National Post, The Globe and Mail, BNN, Chatelaine, Business in Vancouver and more. Penny Green is also a published author for Forbes and a member of the invite-only, Forbes Technology Council.

Jeff B. Smith
MBA, BA
Chairman of the Advisory Board, The Yield Growth Corp.

Jeff-teampage-uai-552x736.jpg

Jeff Smith is the Global Chief Transformation Officer at Johnson & Johnson Consumer Companies, the world’s largest and most diversified healthcare company with worldwide sales of US$76 billion in 2017.

In his most recent role as Johnson & Johnson Company Group Chairman for Consumer North America, Jeff delivered strong organic growth, new growth levers such as Beauty Special Ops and the OceanX partnership, and oversaw several important strategic acquisitions including Vogue International LLC, La Lumière and Neostrata. His division represented more than 42% of global revenue delivering over US$6.5 billion in annual revenue with mid-single digit growth rates; spent over US$1 billion in marketing investment; delivered consistent market share gains and doubled the regional profitability. Jeff continues to serve on the Johnson & Johnson’s Group Operating Committee Executive.

Prior to acting as Chairman of Johnson & Johnson, in 2011 Jeff was appointed President, U.S. Skincare in the newly formed North American region. Jeff had full P&L responsibility for the Baby (JOHNSON’S®, AVEENO®) and Beauty Care divisions (NEUTROGENA®, AVEENO®, CLEAN & CLEAR®, LUBRIDERM® and KORRES® Natural products) within the United States. As President of Johnson & Johnson’s largest business unit, Jeff grew it from the 3rd largest skincare company to #1 in the U.S. over 3.5 years.

Jeff began his career with Johnson & Johnson Inc. Canada, progressing through a number of sales assignments, becoming Vice President Sales in 1997. Jeff became President U.S. Wound Care, and Worldwide Franchise Vice President, in 1999. In 2003, he was appointed President, Johnson & Johnson Inc., Canada and led the successful integration of Johnson & Johnson Inc., McNeil Consumer Healthcare and Pfizer Consumer Healthcare in 2008. Prior to Johnson & Johnson, he worked for Procter & Gamble in Vancouver, B.C. in various sales management positions. He is deeply committed to the safety and health of consumers, and serves on numerous industry boards, including the Board of Directors of the Personal Care Products Council.

Born and raised in Canada, Jeff holds an MBA from Edwards School of Business, University of Saskatchewan and a BA in Economics, University of Saskatchewan. He is married, has 2 children and lives in Toronto, Canada.

Rick Huang
MBA, CPA
CFO, The Yield Growth Corp.

Get-The-Shot-Studios-Photo-by-Mark-Whitehead-203-uai-1333x1777.jpg

Rick Huang served as CFO of Hanwei Energy Services corporation (TSX: HE). Rick has also served as CFO of other publicly traded companies where he has managed all aspects of finance, banking, compliance, accounting, reporting, internal control, admin, supporting the board of directors in financial oversight. He also has supervised all aspects of accounting for various subsidiary companies in Canada, China, Russia and Kazakhstan and consolidations under IFRS. He has worked on investor relations activities, roadshows AGM preparations, and licensing agreements and has led various public equity financing projects raising funds of up to $90 million and leading acquisitions of up to $80 million. Rick has done negotiations for international joint ventures, including drafting shareholders’ agreements, establishing international legal entities, and assets transfers. Rick also serves as Chair of the Audit Committee for Datable Technology Corp. (TSXV: TTM) and previously Chair of the Governance Committee and member of the Audit Committee of Poydras Gaming Finance Corp. (TSXV: PYD)

Amy Frankel
JD, BA
Vice President Licensing & General Counsel, The Yield Growth Corp.

amy-headshot-new-uai-552x737.jpg

Amy Frankel has over 15 years of experience working with consumer product companies. In her various roles as in-house counsel, Amy has gained vast experience building, protecting and expanding international brands. Previously, Amy was Co-General Counsel of Aritzia LP (TSX: ATZ) and Associate General Counsel of Skechers USA Inc. (NYSE: SKX). Her expertise includes negotiating inbound and outbound licensing deals, developing intellectual property strategies and managing international intellectual property portfolios. Amy’s experience also includes corporate governance for private and public US and Canadian companies, as well as a wide breadth of commercial matters, including distribution agreements and technology contracts. Amy started her career as a business litigator in Los Angeles, appearing before numerous state and federal courts before moving in-house with Skechers. Amy practiced law in California for 10 years prior to moving to Vancouver, BC. In 2008, she was admitted to the Law Society of British Columbia. Amy obtained her Bachelor’s degree from the University of California, Santa Barbara and her Juris Doctorate from the University of California, Hastings. She is licensed in California and British Columbia.

Sandi Lesueur
President, Urban Juve Provisions Inc.

sandi-teampage-uai-552x736.jpg

Highlights of Sandi Lesueur’s professional experience include the design and launch of several product lines for physicians and celebrities such as dermatologist Dr. Jason Rivers, and Oprah Winfrey’s makeup artist, Derrick Rutledge at OOH Lifestyle. Over her eight-year tenure, she played part in the meteoric rise of M.A.C Cosmetics where she developed expertise to recognize and situate innovative brands as future dominant players in the cosmetics business.

Her health and wellness knowledge — combined with experience in global production, distribution and brand cohesion — will position the newly launched Urban Juve as a unique force in a lucrative, growing sector in full-spectrum health.

Spiros Margaris
Director, The Yield Growth Corp.

spiros.jpg

Spiros Margaris, holder of a Master’s in Business Administration from the University of Toronto and is a venture capitalist and thought leader in the FinTech and InsurTech industries. He is a frequent speaker at international FinTech and InsurTech conferences and publishes articles on innovation and thought leadership.

Krystal Pineo
Director, The Yield Growth Corp.

Get-The-Shot-Studios-Photo-by-Mark-Whitehead-122-uai-1333x1777.jpg

Krystal has 8 years of venture capital experience, as an early stage investor and fund raiser. Krystal is the founder, chief financial officer and director of KP Capital Inc, a family office that invests in early stage start-ups, as well as providing corporate advisory services. She is also a director of Antler Retail Inc., an international retail cannabis chain. Krystal has also championed women empowerment causes and has done charitable work and fund raising for the Portland Hotel Society, a lower east side women’s shelter providing recovery services for marginalized homeless women.

OUR TEAM
https://yieldgrowth.com/about/

3
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 938

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 240

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 490

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 188

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 150

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 462

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 235

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 289

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 309

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 261

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading

Top 5 Most Recently Viewed Articles

Sonic Partners with Obsessed Garage for Home Garage Solutions

Updated Category News Views 147

Sonic Teams Up with Obsessed Garage to Transform Home Garages Sonic, a front-runner in delivering high-quality tool solutions and equipment, has recently announced an exciting partnership with Obsessed Garage. This collaboration aims to cater to home garage enthusiasts who demand tools and storage solutions that match the quality standards utilized by professionals in the...

Continue Reading
Investors of Sun Communities, Inc. Urged to Act Before Deadline

Updated Category News Views 167

Important Update for Sun Communities, Inc. Investors There is a significant call to action for investors of Sun Communities, Inc. as a class action lawsuit has been filed against the company, urging those affected to act promptly. This is a crucial moment for investors who purchased securities from the company during a specific period. Legal representation is being...

Continue Reading
XOMA Stock Reaches New Heights: Key Developments and Insights

Updated Category News Views 67

XOMA Stock Performance Overview XOMA Ltd's stock has recently made headlines by reaching a remarkable 52-week high, with shares trading at an impressive $30.49. This achievement not only signifies a significant milestone for the company but also highlights a robust year-over-year growth that can't be overlooked. Investors have observed a substantial increase of 73.82% in...

Continue Reading
Evolv Technologies Faces Turmoil with Executive Departures

Updated Category News Views 230

Evolv Technologies Faces Turmoil with Executive Departures Evolv Technologies Holdings (NASDAQ: EVLV) is navigating turbulent times following the resignation of its Chief Financial Officer, Mark Donohue. His departure comes amid serious allegations of improper revenue recognition practices that have raised questions about the company's integrity and financial health....

Continue Reading
Editas Medicine: Financial Insights and Market Strategies Revealed

Updated Category News Views 56

Editas Medicine Maintains Price Target Amidst Financial Developments Recently, Leerink Partners reaffirmed a Market Perform rating for Editas Medicine (NASDAQ: EDIT), keeping a price target steady at $8.00. This decision comes closely after the company announced a substantial financing agreement with DRI Healthcare Trust. Under this agreement, Editas is set to receive an...

Continue Reading